TMO — Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Performance:

  • Revenue: $12.21 billion (up 7% YoY)
  • Adjusted Operating Income: $2.88 billion (up 6% YoY)
  • Adjusted Operating Margin: 23.6%
  • Adjusted EPS: $6.57 (up 8% YoY)

• Full Year 2025 Performance:

  • Revenue: $44.56 billion (up 4% YoY)
  • Adjusted Operating Income: $10.11 billion (up 4% YoY)
  • Adjusted Operating Margin: 22.7%
  • Adjusted EPS: $22.87 (up 5% YoY)

2. Strategic Updates and Business Highlights

• Market Performance:

  • Pharma and biotech segments showed high single-digit growth in Q4, driven by bioproduction and clinical research.
  • Academic and government markets faced low single-digit declines due to macroeconomic conditions.
  • Industrial and applied markets grew slightly for the year, while diagnostics and healthcare remained flat.

• Growth Strategy:

  • Focused on high-impact innovation, trusted partnerships, and a strong commercial engine.
  • Key product launches included advancements in mass spectrometry and bioproduction technologies.
  • Strategic partnerships with organizations like OpenAI and Chan Zuckerberg for enhanced capabilities.

• Capital Deployment:

  • Approximately $16.5 billion deployed in 2025, including $13 billion on M&A and $3.6 billion returned to shareholders.
  • Notable acquisitions included the filtration business from Solventa and a sterile fill-finish site from Sanofi.

3. Forward Guidance and Outlook

• 2026 Guidance:
  • Revenue expected between $46.3 billion and $47.2 billion, representing 4% to 6% growth.
  • Adjusted EPS guidance of $24.22 to $24.80, indicating 6% to 8% growth.
  • Assumes 3% to 4% organic growth and includes a $300 million revenue tailwind from foreign exchange.

4. Bad News, Challenges, or Points of Concern

• Market Pressures:

  • Academic and government segments remain cautious, with potential delays in spending until a finalized NIH budget is passed.
  • The company faces ongoing headwinds from tariffs and foreign exchange volatility, impacting margins.
  • Declines in the academic market and pressures in China were noted as challenges.

• Operational Risks:

  • The guidance does not account for potential future changes in tariffs or their impact on foreign exchange rates.
  • The integration of recent acquisitions may present challenges in achieving projected synergies.

5. Notable Q&A Insights

• Market Conditions:

  • Management expressed cautious optimism regarding biopharma spending, noting a lag between funding flows and actual spending.
  • The sentiment among pharma customers appears positive, with expectations for increased activity in 2026.

• Analytical Instruments Performance:

  • The segment faced a tough comparison but managed to maintain flat growth, supported by strong performance in pharma and biotech.

• Customer Engagement:

  • Management highlighted the importance of being a trusted partner, with positive feedback from customers indicating a willingness to collaborate on specific projects.

Overall, Thermo Fisher Scientific closed 2025 with strong financial performance and a positive outlook for 2026, despite facing challenges in certain market segments and external economic pressures.